In a study by Yoshimura et al., PD-L1 expression was not found to be associated with the efficacy of docetaxel + ramucirumab in NSCLC patients who progressed on platinum-based chemotherapy [22]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.